In this article, we look at how Mesh Bio and MultiOmic Health use AI to transform and improve the lives of metabolic syndrome patients through patient stratification and precision medicine.
We are excited to announce our feature in the most recent edition of Nature Portfolio’s Biopharma Dealmakers discussing the advances in AI-driven drug development.